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Abstract
Background:  Bisphosphonate therapy has been readily accepted as standard of care for
individuals with bone metastases from breast cancer. In this study we determined whether the
proportion of patients experiencing a skeletal related event (SRE) in a clinical practice population
was similar to that observed in phase III randomized controlled studies.
Methods: A retrospective chart review was conducted of 110 patients receiving intravenous
bisphosphonates for advanced breast cancer. The proportion of patients experiencing at least one
SRE after 12 months of therapy was determined. SRE included vertebral or non-vertebral fracture,
cord compression, surgery and/or radiotherapy to bone.
Results: The proportion of patients who had an SRE was 30% (28 individuals) and the median time
to first event was greater than 350 days. Non-vertebral events and radiotherapy were the most
frequent type of SRE, while cord compression and hypercalcaemia were rare (1%). Most patients
in the study had bone-only disease (58.2%) and most had multiple bone lesions. In the first 12
months the mean duration of exposure to intravenous bisphosphonates was 261 days and most
patients remained on treatment until just before death (median 27 days).
Conclusion: This study suggests that the rate of clinically relevant SREs is substantially lower than
the event rate observed in phase III clinical trials. We attribute this lower rate to observational bias.
In the clinical trial setting it is possible that over-detection of skeletal events occurs due to the
utilisation of regular skeletal survey or radionucleotide bone scan, whereas these procedures are
not routine in clinical practice. Phase IV observational studies need to be conducted to determine
the true benefits of bisphosphonate therapy in order to implement rationale use of
bisphosphonates.
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Background
Randomised controlled studies have consistently demon-
strated that the skeletal complications of metastatic breast
cancer can be reduced by the regular administration of
intravenous bisphosphonates [1-7]. Given the potential
impact of a pathological fracture, it is not surprising that
bisphosphonate therapy has been readily accepted as
standard of care for metastatic bone disease [8-10]. How-
ever, this therapy is expensive, and since bisphosphonates
have no impact on survival, their cost-effectiveness is pri-
marily justified by the avoidance of radiotherapy or sur-
gery [11,12].
To date, clinical trials of bisphosphonate therapy have
failed to determine the optimal frequency of administra-
tion, timing of initiation or duration of use [9]. In prac-
tice, patients are treated on a three to four weekly basis for
an indefinite period. Until their death, individuals with
advanced cancer are therefore exposed to the risk of infu-
sion-related adverse events, the possibility of nephrotoxic-
ity, and the inconvenience of intravenous treatment. In an
effort to promote rational prescribing of bisphospho-
nates, a number of medical and funding agencies have
developed treatment guidelines which include rules for
initiation and cessation of treatment [9,10]. Unfortu-
nately, recent studies have demonstrated that adherence
to these guidelines is universally poor [10,13,14]. We pro-
pose that prescribing habits are unlikely to change with-
out evidence of the efficacy, impact on quality of life, and
cost-effectiveness of bisphosphonates in routine clinical
practice.
To the knowledge of the investigators, there has been no
report of the outcomes of patients receiving bisphospho-
nates outside the conduct of a clinical trial. Given the
impact of inappropriate prescribing, it seems unreasona-
ble to assume that the benefits observed in randomized
controlled studies will be perfectly replicated in a clinical
practice population. Furthermore, individuals in the key
randomized studies underwent regular skeletal surveys,
and the skeletal-related events (SRE) identified in these
trials represented the composite of clinically relevant as
well as asymptomatic radiological changes [1-6]. Skeletal
surveys are not used routinely in clinical practice, and thus
only clinically relevant skeletal events are likely to be
identified in this setting. In this study, we report the
results of an audit of intravenous bisphosphonate use in
patients with metastatic breast cancer in the setting of rou-
tine clinical practice.
Methods
Study cohort
110 women with metastatic breast cancer were included
in this study. They had commenced intravenous pamidr-
onate or zoledronic acid for the prophylaxis of skeletal
complications between January 1998 and September
2003. Patients were excluded if they were receiving
bisphosphonates therapy for osteoporosis or for the man-
agement of tumour-related hypercalcaemia. Individuals
were identified through the pharmacy records of two large
comprehensive cancer centers in Australia; St Vincent's
Hospital, Darlinghurst, NSW, and St George Hospital,
Kogarah, NSW. The dataset was extracted from medical
and pharmacy records by three investigators (AL, RD, ES)
and entered into a standardised data collection form. A
random sample of forms was audited by an independent
investigator (WL) and data queries were resolved by case
review by three investigators (WL, ES, RW). Relevant clin-
ical information as well as the details of bisphosphonates
usage was recorded on each person for a period of 12
months from the time of commencement of bisphospho-
nate therapy.
The primary outcome measure used in this study was the
proportion of patients experiencing at least one SRE in a
12 month period following the commencement of intra-
venous bisphosphonate therapy. SRE were defined as
either a pathological fracture, a bony lesion requiring
intervention (surgery or radiotherapy) for pain or preven-
tion of skeletal complications, spinal cord compression or
hypercalcaemia of malignancy. The total number of SRE
did not include events occurring within 30 days of com-
mencement of intravenous bisphosphonate therapy if
they were related to the index presentation of bony dis-
ease. Simultaneous SRE (i.e. presenting on the same day)
were counted as one event. Treatment of a single lesion
with radiotherapy and surgery were not coded as separate
SREs.
The study was conducted under guidelines consistent with
the NHMRC National Statement of Ethical Conduct in
Research Involving Humans.
Statistical analysis
Descriptive statistics were used to define the characteris-
tics of the sample and Kaplan-Meier (KM) estimates were
used to calculate the proportion with an SRE. The KM
technique was used to estimate the time from commence-
ment of bisphosphonate administration to the first SRE.
Only SRE not cancer-related deaths were analysed as
events. All data was analysed using SPSS statistical soft-
ware V11.0 (SPSS Inc., Chicago, IL).
Results
Patient characteristics and bisphosphonate administration
The baseline clinical characteristics of the study cohort are
shown in Table 1. At initiation of bisphosphonates ther-
apy the mean age of the group was 57.2 ± 12.1 years and
most patients (50%) had multiple bone metastases. On
average, skeletal disease had developed 4.2 ± 4.4 yearsBMC Cancer 2005, 5:89 http://www.biomedcentral.com/1471-2407/5/89
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from the primary diagnosis of breast cancer and bisphos-
phonate therapy was commenced at a mean of 291 ± 497
days from the time of diagnosis of bone metastases.
Bisphosphonates were commenced concurrently with
chemotherapy (either alone or with hormone therapy) in
54.4% of patients, with hormonal therapy in 40.4% of
patients, and without any systemic treatment in 5.3% of
individuals. In the first 12 months the mean duration of
exposure to intravenous bisphosphonates was 261 days,
and a total of 60 patients (54.5%) remained on therapy
beyond the 12 month observation period. The mean and
median number of infusions of intravenous bisphospho-
nates in the first 12 months of follow-up was 9 and 12
respectively. Over the total duration of follow-up a mean
of 16 cycles of IV bisphosphonate were received, with an
upper range of 56 cycles. The reasons for discontinuation
of bisphosphonates within the 12 month observation
period were cancer death (24 patients, 22%); change to
oral bisphosphonates (13 patients, 12%); intolerance (5
patients, 4.5%) or not specified (3 patients, 2.7%). A sig-
nificant number of patients remained on therapy despite
being close to death from cancer progression. In the 24
patients who died within the study period, the time from
last documented bisphosphonate infusion to death was
between 2 and 140 days with a median of 27 days.
Although bisphosphonate treatment guidelines state that
an abnormal bone scan without evidence of bone destruc-
tion does not justify the initiation of bisphosphonates, we
found that 21% (23 individuals) of individuals in this
audit had commenced treatment on this basis.
Skeletal complications
The proportion of patients experiencing at least one SRE
within 12 months of commencing bisphosphonates was
30% (28 individuals). The characteristics of these events,
and the proportion of patients experiencing them, are
described in Table 2. Spinal cord compression and hyper-
calcaemia were rare events, occurring in only 1% of indi-
viduals within the study period. The median time to the
first occurrence of a SRE was greater than 365 days (Figure
1). Within the 12 month observation period, nine of 28
individuals developed a second SRE at a mean of 223 days
from bisphosphonate initiation, and of these six were still
undergoing treatment with bisphosphonate at the time of
Table 1: Disease characteristics of patients
Number of patients Percent (%)
Sites of extra-osseous disease
None 64 58.2
Liver Only 14 12.7
Brain Only 1 0.9
Lung Only 3 2.7
Multiple 11 10.0
Other 15 13.6
Unknown 2 1.8
Number of bone lesions
11 0 9 . 1
2–5 40 36.4
>5 55 50.0
Unknown 5 4.5
Treatment prior to bisphosphonates
Nil 33 30.0
Chemotherapy +/- hormone 31 28.2
Hormone therapy alone 46 41.8
Hormone therapy prior to bisphosphonates
1st line 31 28.2
2nd line 19 17.3
3rd line 3 2.7
Not applicable 57 51.8
Median survival from start of bisphosphonates Days (95% CI)
All subjects 818 (644–911)
Subjects with bone metastases only 998 (653–1342)
Subjects with extra-osseous metastases 513 (339–686)
* based on available imaging, either bone scan, skeletal survey, CT or MRI.BMC Cancer 2005, 5:89 http://www.biomedcentral.com/1471-2407/5/89
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the second SRE. Three individuals developed a fourth SRE
and one a fifth SRE within 12 months of starting
bisphosphonates.
Interestingly, when patients with bone scan only disease
were excluded from the analysis the cumulative propor-
tion of individuals developing a SRE within the first year
of commencing bisphosphonates was 32% (23 of 87
patients). There was no statistically significant difference
between subjects with bone scan-only detected metastases
and the remainder of the cohort in the proportion of sub-
jects with an SRE in the first 12 months (p = 0.77). This
data suggests that bone scan only disease does not repre-
sent a better prognostic group of patients.
Discussion
Over 80% of women with metastatic breast cancer have
bone metastases [15,16], yet a much smaller proportion
of these will develop clinically apparent complications
related to bone destruction. One large retrospective study
performed before the introduction of bisphosphonates
demonstrated that 29% of individuals develop a clinically
significant SRE [15]. This figure is comparable to the find-
ings of the current study (30%) yet different from the
results of the randomized controlled trials of intravenous
bisphosphonates [1-6]. In these latter studies, the propor-
tion of individuals who experienced at least one skeletal
complication at 12 months from bisphosphonate com-
mencement was 43% in the treatment arm compared with
56% in the placebo arm. We propose that the discrepancy
between the results of the randomized controlled studies
and our current audit relates primarily to the use of regu-
lar radiographic skeletal surveys in the trial setting [4]. In
practice, skeletal events are only identified on the basis of
clinical suspicion and thus many bone lesions may be
appropriately undetected and untreated. The corollary is
of course that intensive exposure to skeletal surveys may
result in the treatment of lesions which may never become
clinically significant.
The baseline population risk of a skeletal event is a further
factor which may explain the discrepancies between the
current audit and the results of previous randomized con-
trolled studies. Patients with metastatic disease limited to
bone are four times more likely to fracture a long bone
than those with concurrent liver and bony metastases,
while individuals with extensive metastasis involving long
bones are more likely to develop a fracture than those
with solitary metastases [17]. In terms of these risk factors,
our patient population was certainly at no lesser risk of
fracture than the individuals enrolled in the studies of
Hortobagyi et al [1,2] and Theriault [3]. The percentage of
individuals with metastatic disease limited to bone was
comparable at 58.2% (current audit), 60% (Hortobagyi
studies) and 70% (Theriault et al,). Furthermore, only
9.1% of the subjects in the current study had a solitary
bone metastasis, whereas 43% of patients in the Horto-
bagyi studies had an isolated lesion [1,2].
The endpoint used in this study, specifically the propor-
tion of patients with more than one SRE is well accepted
and provides readily assessable and comparable estima-
tions of treatment effect. It however only captures infor-
mation about the first event and does not measure the
multiple skeletal events which sometimes occur in a single
individual. While acknowledging that the impact of
bisphosphonate therapy on recurrent events is important
the best way to measure and analyse this data is
Table 2: Proportion of patients having each type of SRE in the first 12 months of intravenous bisphosphonate therapy
Number of patients ¥Proportion with event (%)
Type of SRE
Pathological fracture 7 9%
Cord compression 1 1%
Other 20 23%
Site of SRE
Vertebral 9 10%
Non-vertebral 17 22%
Hypercalcaemia 1 1%
Treatment for SRE
Radiotherapy 17 21%
Surgery 3 4%
Medical+ 81 0 %
¥Kaplan-Meier estimates of the proportion with a complication. + Medical includes change in analgesics, hormonal treatment or chemotherapy.BMC Cancer 2005, 5:89 http://www.biomedcentral.com/1471-2407/5/89
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controversial [18-21]. For this reason, we chose not to
evaluate secondary endpoints such as total number of
SRE, and event rate in the current audit.
Given the relative risk reduction in skeletal related events
bisphosphonates clearly have a place in the management
of women with metastatic bone disease. It is uncertain
however what the absolute benefits of these reductions
are, whether in terms of SRE, or economic endpoints. The
rationale use of these agents is hindered by a lack of data
concerning drug scheduling, duration of use, indications
for initiation and cessation [9]. This audit highlights the
fact that while these questions remain unanswered, clini-
cians will be reluctant to alter current prescribing habits.
Most patients remained on bisphosphonates despite a
declining performance status; the drugs were indefinitely
administered on a three-four weekly basis and 67% of
patients who experienced a second SRE continued
bisphosphonate therapy.
Conclusion
The findings of this study provide an additional impetus
to proceed with post-marketing evaluation of the use of
bisphosphonates in clinical practice.
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